Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Companies

Lipocine

Lipocine develop branded products using its proprietary drug delivery technologies. They provide discovery and delivery support for challenging drugs. They issued 14 patents and corporate partnerships

The company in detail

Profile

Lipocine was formed in 1997 to develop new branded drug products by improving currently marketed compounds by leveraging its lipid based technologies protected by 14 issued patents (20 patents pending).

Lipocine’s technologies include Lip’ral® for the optimal oral absorption of poorly water soluble drugs, Lip’ral® SSR for the controlled release of poorly water soluble drugs and Hydroance ® for the oral delivery of highly water soluble compounds, including macromolecules.

Lipocine develops its products through various value points and then seeks licensing partners for further development and commercialization. Most products utilize the FDA 505(b) (2) regulatory pathway (generally 18-24 months from project inception to PK only filing). Lipocine has licensed several products to corporate partners.

Currently Lipocine has 8 candidates in its product pipeline, indicated for diseases such as stoke, hormonal and respiratory disorders. Lipocine Technology can be applied to any poorly water soluble drug (~40% of all drugs), and poorly permeable drugs with absorption issues.

Lipocine can provide the following improvements for currently marketed drugs:

  • Reduced dosing.
  • Lower dose.
  • Elimination of food restriction.
  • Controlled release for poorly water soluble drugs.
  • Reduced inter-patient variability.
  • Reduction of side effects.
  • Non invasive delivery options.
Lipocine was founded by Drs. William Higuchi (co-founder of Theratech-sold to Watson) and Mahesh Patel (Upjohn).

Partnering strategy/interests

Lipocine is seeking potential partners with strong marketing, manufacturing and late stage clinical capabilities in place for each specific product available for license.
Products can be licensed to partners for an up-front licensing fee, milestones and royalty. Initial therapeutic categories of interest are hormone therapy, CNS/Pain, immunosupression, cardiovascular and respiratory.
 

Out-licensing

LPCN 1002 is a branded product for female hormonal disorders currently in Phase I studies specifically targeting Endometrial hyperplasia and secondary amenorrhea. More
Targeting hypertension, LPCN 1010 is a once-a-day antihypertensive beta blocker with alpha activity. More
Immunosupressant product, bioequivalent to reference product More
Oral candidate created to replace androgen, with the potential of being the first oral bio replacement product in the U.S. More
A once - a - day balanced NSAID targeted for acute pain especially post-operative pain and migraine. More
Lipocine is developing LPCN 1029D as an approved indication for osteoarthritis and rheumatoid arthritis More
LPCN 1035 is being developed as a longer acting version of a leading respiratory product, specifically as a non-sedating, non-narcotic anti-tussive. More
Indicated specifically for subarachnoid hemorrhage, LPCN 1038 also has potential indications for migraine prophylaxis and glaucoma. More
LPCN 1012 is a branded product for intermittent claudication and has completed phase I studies More

R&D

To view this information, you must subscribe to Partneringtools.

Partnerships

To view this information, you must subscribe to Partneringtools.

Deals

To view this information, you must subscribe to Partneringtools.

Press Releases

(19th Sep 2007) CHESTER, N.J. and SALT LAKE CITY (Sept. 19, 2007) - Adams Respiratory Therapeutics, Inc. today announced that they have entered into a license and collaboration agreement to develop new prescription adult cough products. More

Senior management

To view this information, you must subscribe to Partneringtools.

Board of directors

To view this information, you must subscribe to Partneringtools.
Partnering consultation free of charge
MipTec
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us